Critical Contrast: Aegerion Pharmaceuticals (AEGR) versus Neos Therapeutics (NEOS)
Aegerion Pharmaceuticals (NASDAQ: AEGR) and Neos Therapeutics (NASDAQ:NEOS) are both small-cap pharmaceuticals – nec companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.
This is a summary of recent recommendations and price targets for Aegerion Pharmaceuticals and Neos Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aegerion Pharmaceuticals currently has a consensus price target of $1.50, suggesting a potential downside of 23.86%. Neos Therapeutics has a consensus price target of $16.20, suggesting a potential upside of 55.40%. Given Neos Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Neos Therapeutics is more favorable than Aegerion Pharmaceuticals.
Insider and Institutional Ownership
84.9% of Aegerion Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.5% of Neos Therapeutics shares are owned by institutional investors. 4.6% of Aegerion Pharmaceuticals shares are owned by insiders. Comparatively, 5.2% of Neos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Aegerion Pharmaceuticals and Neos Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Aegerion Pharmaceuticals and Neos Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Neos Therapeutics||$9.15 million||31.17||-$83.33 million||($3.42)||-3.05|
Aegerion Pharmaceuticals has higher revenue, but lower earnings than Neos Therapeutics. Neos Therapeutics is trading at a lower price-to-earnings ratio than Aegerion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Neos Therapeutics beats Aegerion Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
Receive News & Ratings for Aegerion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.